FMT

FMT

2901 bookmarks
Custom sorting
Age-dependent modulation of gut microbiome in response to tumor immunomodulation - PubMed
Age-dependent modulation of gut microbiome in response to tumor immunomodulation - PubMed
In-situ vaccination (ISV) utilizing nanoparticles (NPs) and therapeutic devices like focused ultrasound (FUS) can trigger immune-mediated killing of both treated and untreated cancer cells. However, the impact of confounding factors such as aging and gut microbiota composition on therapeutic outcome …
·pubmed.ncbi.nlm.nih.gov·
Age-dependent modulation of gut microbiome in response to tumor immunomodulation - PubMed
Aged gut microbiota contribute to different changes in antioxidant defense in the heart and liver after transfer to germ-free mice - PubMed
Aged gut microbiota contribute to different changes in antioxidant defense in the heart and liver after transfer to germ-free mice - PubMed
Age-associated impairment in antioxidant defense is an important cause of oxidative stress, and elderly individuals are usually associated with gut microbiota (GM) changes. Studies have suggested a potential relationship between the GM and changes in antioxidant defense in aging animals. Direct evid …
·pubmed.ncbi.nlm.nih.gov·
Aged gut microbiota contribute to different changes in antioxidant defense in the heart and liver after transfer to germ-free mice - PubMed
A Comparison of Methods of Gut Microbiota Transplantation for Preclinical Studies - PubMed
A Comparison of Methods of Gut Microbiota Transplantation for Preclinical Studies - PubMed
The experimental details reported in preclinical fecal microbiota transplantation (FMT) protocols are highly inconsistent, variable, and/or incomplete. We therefore evaluated FMT from a human donor to antibiotic-induced microbial-depleted mice by exploring the effects of six techniques based on anti …
·pubmed.ncbi.nlm.nih.gov·
A Comparison of Methods of Gut Microbiota Transplantation for Preclinical Studies - PubMed
The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation - PubMed
The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation - PubMed
(1) Background: Fecal microbiota transplantation (FMT) is an effective treatment for ulcerative colitis (UC). Metabolomic techniques would assist physicians in clinical decision-making. (2) Methods: Patients with active UC undergoing FMT were enrolled in the study and monitored for 3 months. We expl …
·pubmed.ncbi.nlm.nih.gov·
The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation - PubMed
Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review - PubMed
Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review - PubMed
Neurogenic hypertension, a complex and multifactorial cardiovascular disorder, is known to be influenced by various genetic, environmental, and lifestyle factors. In recent years, there has been growing interest in the role of the gut microbiome in hypertension pathogenesis. The bidirectional commun …
·pubmed.ncbi.nlm.nih.gov·
Unraveling mechanistic insights into the role of microbiome in neurogenic hypertension: A comprehensive review - PubMed
The role of microbiome-based therapeutics for antimicrobial-resistant organism colonization - PubMed
The role of microbiome-based therapeutics for antimicrobial-resistant organism colonization - PubMed
The gut is host to a diverse array of microbiota that constitute a complex ecological system crucial to human physiology. Disruptors to the normal host microbiota, such as antimicrobials, can cause a loss of species diversity in the gut, reducing its ability to resist colonization by invading pathog …
·pubmed.ncbi.nlm.nih.gov·
The role of microbiome-based therapeutics for antimicrobial-resistant organism colonization - PubMed
Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial - PubMed
Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial - PubMed
ClinicalTrials.gov NCT03244644 (https://clinicaltrials.gov/ct2/show/NCT03244644).
·pubmed.ncbi.nlm.nih.gov·
Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial - PubMed
FDA-approved microbiome therapy reduces recurrent CDI, regardless of risk factors
FDA-approved microbiome therapy reduces recurrent CDI, regardless of risk factors
An FDA-approved oral fecal microbiota therapeutic reduces the risk for recurrent Clostridioides difficile infection in high-risk patients compared with placebo, regardless of demographics or baseline risk factors, researchers reported.
·news.google.com·
FDA-approved microbiome therapy reduces recurrent CDI, regardless of risk factors
The role of microbiome-based therapeutics for antimicrobial-resistant organism colonization - PubMed
The role of microbiome-based therapeutics for antimicrobial-resistant organism colonization - PubMed
The gut is host to a diverse array of microbiota that constitute a complex ecological system crucial to human physiology. Disruptors to the normal host microbiota, such as antimicrobials, can cause a loss of species diversity in the gut, reducing its ability to resist colonization by invading pathog …
·pubmed.ncbi.nlm.nih.gov·
The role of microbiome-based therapeutics for antimicrobial-resistant organism colonization - PubMed
Building a Better Microbiome - proto.life
Building a Better Microbiome - proto.life
Stephanie Culler is using genetically engineered, synthetic probiotics to overhaul treatments for a host of ailments.
·news.google.com·
Building a Better Microbiome - proto.life
Microbiome analysis and fecal microbiota transfer in pediatric gastroenterology - a structured online survey in German-speaking countries - PubMed
Microbiome analysis and fecal microbiota transfer in pediatric gastroenterology - a structured online survey in German-speaking countries - PubMed
Guidelines for microbiome analyses and FMT in pediatric patients and clinical studies investigating their benefits are absolutely necessary to improve the patient-centered care in pediatric gastroenterology. The long-term and successful establishment of pediatric FMT centers with standardized proced …
·pubmed.ncbi.nlm.nih.gov·
Microbiome analysis and fecal microbiota transfer in pediatric gastroenterology - a structured online survey in German-speaking countries - PubMed
[Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation] - PubMed
[Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation] - PubMed
Objective: To investigate the clinical efficacy of fecal microbiota transplantation (FMT) for treating steroid-refractory gastrointestinal acute graft-versus-host disease (GI-aGVHD) . Methods: This analysis included 29 patients with hematology who developed steroid-refractory GI-aGVHD …
·pubmed.ncbi.nlm.nih.gov·
[Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation] - PubMed
Oral and gut microbiome alterations in heart failure: Epidemiology, pathogenesis and response to advanced heart failure therapies - PubMed
Oral and gut microbiome alterations in heart failure: Epidemiology, pathogenesis and response to advanced heart failure therapies - PubMed
Despite significant advances in therapies, heart failure (HF) remains a progressive disease that, once advanced, is associated with significant death and disability. Cardiac replacement therapies with left ventricular assist device (LVAD) and heart transplantation (HT) are the only treatment options …
·pubmed.ncbi.nlm.nih.gov·
Oral and gut microbiome alterations in heart failure: Epidemiology, pathogenesis and response to advanced heart failure therapies - PubMed
Profiling the Fungal Microbiome after Fecal Microbiota Transplantation for Graft-versus-Host Disease: Insights from a Phase 1 Interventional Study - PubMed
Profiling the Fungal Microbiome after Fecal Microbiota Transplantation for Graft-versus-Host Disease: Insights from a Phase 1 Interventional Study - PubMed
Disruption of the intestinal bacterial microbiota is frequently observed in the context of allogeneic hematopoietic cell transplantation (HCT) and is particularly pronounced in patients who develop graft-versus-host disease (GVHD). Donor fecal microbiota transplantation (FMT) restores gut microbial …
·pubmed.ncbi.nlm.nih.gov·
Profiling the Fungal Microbiome after Fecal Microbiota Transplantation for Graft-versus-Host Disease: Insights from a Phase 1 Interventional Study - PubMed
Psychobiotics and fecal microbial transplantation for autism and attention-deficit/hyperactivity disorder: microbiome modulation and therapeutic mechanisms - PubMed
Psychobiotics and fecal microbial transplantation for autism and attention-deficit/hyperactivity disorder: microbiome modulation and therapeutic mechanisms - PubMed
Dysbiosis of the gut microbiome is thought to be the developmental origins of the host's health and disease through the microbiota-gut-brain (MGB) axis: such as immune-mediated, metabolic, neurodegenerative, and neurodevelopmental diseases. Autism spectrum disorder (ASD) and attention-deficit/hypera …
·pubmed.ncbi.nlm.nih.gov·
Psychobiotics and fecal microbial transplantation for autism and attention-deficit/hyperactivity disorder: microbiome modulation and therapeutic mechanisms - PubMed
Microbiota as the unifying factor behind the hallmarks of cancer - PubMed
Microbiota as the unifying factor behind the hallmarks of cancer - PubMed
The human microbiota is a complex ecosystem that colonizes body surfaces and interacts with host organ systems, especially the immune system. Since the composition of this ecosystem depends on a variety of internal and external factors, each individual harbors a unique set of microbes. These differe …
·pubmed.ncbi.nlm.nih.gov·
Microbiota as the unifying factor behind the hallmarks of cancer - PubMed
Faecal metabolome and its determinants in inflammatory bowel disease
Faecal metabolome and its determinants in inflammatory bowel disease
Objective Inflammatory bowel disease (IBD) is a multifactorial immune-mediated inflammatory disease of the intestine, comprising Crohn’s disease and ulcerative colitis. By characterising metabolites in faeces, combined with faecal metagenomics, host genetics and clinical characteristics, we aimed to unravel metabolic alterations in IBD.Design We measured 1684 different faecal metabolites and 8 short-chain and branched-chain fatty acids in stool samples of 424 patients with IBD and 255 non-IBD controls. Regression analyses were used to compare concentrations of metabolites between cases and controls and determine the relationship between metabolites and each participant’s lifestyle, clinical characteristics and gut microbiota composition. Moreover, genome-wide association analysis was conducted on faecal metabolite levels.Results We identified over 300 molecules that were differentially abundant in the faeces of patients with IBD. The ratio between a sphingolipid and L-urobilin could discriminate between IBD and non-IBD samples (AUC=0.85). We found changes in the bile acid pool in patients with dysbiotic microbial communities and a strong association between faecal metabolome and gut microbiota. For example, the abundance of Ruminococcus gnavus was positively associated with tryptamine levels. In addition, we found 158 associations between metabolites and dietary patterns, and polymorphisms near NAT2 strongly associated with coffee metabolism.Conclusion In this large-scale analysis, we identified alterations in the metabolome of patients with IBD that are independent of commonly overlooked confounders such as diet and surgical history. Considering the influence of the microbiome on faecal metabolites, our results pave the way for future interventions targeting intestinal inflammation.Data are available on reasonable request. Tables containing the levels of faecal metabolites and bacterial taxa abundances are provided with the manuscript. The raw metagenomics, host genomics and phenotypic data used in this study are available from the European Genome–Phenome Archive data repository: 1000 Inflammatory bowel disease (IBD) cohort (https://www.ebi.ac.uk/ega/datasets/EGAD00001004194), Lifelines DEEP cohort (https://www.ebi.ac.uk/ega/datasets/EGAD00001001991). This includes submitting a letter of intent to the corresponding data access committees. Codes are publicly available at: [https://github.com/GRONINGEN-MICROBIOME-CENTRE/Fecal\_Metabolites\_IBD][1] [1]: https://github.com/GRONINGEN-MICROBIOME-CENTRE/Fecal_Metabolites_IBD
·gut.bmj.com·
Faecal metabolome and its determinants in inflammatory bowel disease
Cancer: The Next Microbiome Frontier
Cancer: The Next Microbiome Frontier
Three therapeutic regulatory approvals in less than a year signal that the promise of the human microbiome may finally be paying off. All of the approved therapies focus on treating recurrent Clostridium difficile infection, but what is next for the field? With promising oncology-related trial results from a number of researchers and companies such as […]
·insideprecisionmedicine.com·
Cancer: The Next Microbiome Frontier
Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms - PubMed
Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms - PubMed
Fecal microbiota transplantation (FMT) has proven to be an effective treatment for recurrent Clostridioides difficile infection (rCDI) in both adult and pediatric patients. However, as microbiome development is a critical factor in children, it remains unclear whether adult fecal donors can provide …
·pubmed.ncbi.nlm.nih.gov·
Donor-recipient specificity and age-dependency in fecal microbiota therapy and probiotic resolution of gastrointestinal symptoms - PubMed
Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota - PubMed
Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota - PubMed
Decreased muscle mass and function, also known as sarcopenia, is common in patients with cirrhosis and is associated with a poor prognosis. Although the pathogenesis of this disorder has not been fully elucidated, a disordered gut-muscle axis probably plays an important role. Decreased barrier funct …
·pubmed.ncbi.nlm.nih.gov·
Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota - PubMed
The microbial metabolite Urolithin A reduces C. difficile toxin expression and repairs toxin-induced epithelial damage - PubMed
The microbial metabolite Urolithin A reduces C. difficile toxin expression and repairs toxin-induced epithelial damage - PubMed
Therapy for C. difficile infections includes the use of antibiotics, immunosuppressors, and fecal microbiota transplantation (FMT). However, these treatments have several drawbacks, including the loss of colonization resistance, promotion of autoimmune disorders, and the potential for unknown …
·pubmed.ncbi.nlm.nih.gov·
The microbial metabolite Urolithin A reduces C. difficile toxin expression and repairs toxin-induced epithelial damage - PubMed
Prevalence of comorbid factors in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a randomized trial of an oral microbiota-based therapeutic - PubMed
Prevalence of comorbid factors in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a randomized trial of an oral microbiota-based therapeutic - PubMed
In this post-hoc analysis, VOS reduced the risk of rCDI compared with placebo, regardless of baseline characteristics, concomitant medications or comorbidities.
·pubmed.ncbi.nlm.nih.gov·
Prevalence of comorbid factors in patients with recurrent Clostridioides difficile infection in ECOSPOR III, a randomized trial of an oral microbiota-based therapeutic - PubMed
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool - PubMed
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool - PubMed
These experiments demonstrate substantial and rapid inactivation of representative organisms, supporting the potential benefit of VOS manufacturing processes to mitigate risk.
·pubmed.ncbi.nlm.nih.gov·
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool - PubMed